News

XV SDDN meeting 2023, Barcelona

On November 20th and 21st, some members of the Welab’s team attended the XV Spanish Drug Discovery Network (SDDN) meeting,…

A new JMedChem publication from Welab

A new JMedChem publication from…

Discovery of WLB-89462, a New Drug-like and Highly Selective σ2 Receptor Ligand with Neuroprotective Properties”, in the Journal of Medicinal…

Fundación MEDINA and WeLab Barcelona

Fundación MEDINA and WeLab Barcelona

Fundación Medina and WeLab Barcelona have signed a collaboration agreement that allows combining experience and resources for the discovery and…

New Sigma-1 receptor-BiP biosensor

New Sigma-1 receptor-BiP biosensor

Scientists from the Pathology and Experimental Therapeutics Dept., Facultat de Medicina i Ciències de la Salut of the Universitat de…

Taros – Welab collaboration agreement

Taros – Welab collaboration agreement

We are proud to announce that Welab Barcelona, the drug discovery & development platform of Leitat, has signed a strategic…

Pharmacelera-Welab partnership agreement

Pharmacelera-Welab partnership agreement

Pharmacelera, the leading provider of computational tools for hit discovery, and Welab, the leading drug discovery and development platform is…

Where does our logo come from?

Where does our logo come…

https://www.welabbarcelona.com/wp-content/uploads/2023/06/Welab-logo.mp4

Spirify – Welab Barcelona research collaboration

Spirify – Welab Barcelona research…

WeLab Barcelona has reached an agreement with Spirify Pharma for a research collaboration on characterization of Spirify’s proprietary analogs of…

Carcinogenicity studies of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator

Carcinogenicity studies of cizolirtine, a…

Check out the new Welab’s publication on toxicological profile of cizolirtine. Results from two-year rodent oral carcinogenicity studies of cizolirtine,…